Latest Biotech News

LB Pharmaceuticals successfully completed an upsized initial public offering raising $285 million, marking the largest biotech IPO of 2025 and breaking a seven-month dry spell in biotech equity...

Recent advances in gene editing have delivered promising preclinical results in treating rare genetic disorders such as multisystemic smooth muscle dysfunction syndrome (MSMDS). Researchers at...

Groundbreaking studies have revealed that small cell lung cancer (SCLC) cells establish functional synapses with neurons, both in the lung and in brain metastases. These synaptic connections...

A novel study analyzing ChatGPT’s ability to recognize retracted and problematic scientific articles revealed significant shortcomings. Researchers submitted titles and abstracts of 217 retracted...

Innovations in drug delivery and synthetic biology continue to transform therapeutic possibilities. Researchers developed poly-L-histidine-coated mesoporous silica nanoparticles for targeted...

The U.S. House of Representatives has passed legislation that could effectively end most academic research collaborations between the United States and China, reflecting ongoing geopolitical...

Cutting-edge imaging and molecular diagnostic techniques are advancing cancer patient management and neurodegenerative disease detection. University College London and collaborators demonstrated...

The U.S. Food and Drug Administration (FDA) has granted approval to Johnson & Johnson’s Inlexzo, a drug-device combination delivering intravesical gemcitabine for non-muscle invasive bladder...

Merck has ceased its research operations across the UK and canceled plans for a £1.3 billion ($1.31 billion) research center in London, citing insufficient government support and policy challenges...

Capsida Biotherapeutics has suspended its phase I/II clinical trial of CAP-002 gene therapy for STXBP1 encephalopathy following the death of the first enrolled pediatric patient. The trial, which...

The U.S. Food and Drug Administration approved Johnson & Johnson’s drug-device combination system, Inlexzo, for patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive...

LB Pharmaceuticals raised $285 million through an upsized IPO on Nasdaq, signalling renewed investor interest in biotech after a seven-month hiatus. The company plans to use the proceeds to...

Revolution Medicines announced positive Phase I results for daraxonrasib, a multi-selective RAS inhibitor targeting pancreatic ductal adenocarcinoma, leading to plans for a global Phase III...

Imperial College London researchers discovered that ‘‘pirate’’ phages hijack tails from unrelated viruses to infect new bacterial species, expanding antimicrobial resistance spread through...

Researchers at Mass General Brigham engineered and screened base editors for precise correction of a single mutation in the ACTA2 gene responsible for multisystemic smooth muscle dysfunction...

A new immunotherapy candidate, STF-1623, developed by Stanford and Arc Institute researchers, inhibits ENPP1 to prevent degradation of cGAMP, a molecule activating the STING pathway in innate...

Sapio Sciences and Ultima Genomics have partnered to integrate Sapio’s AI-powered lab informatics platform with Ultima’s low-cost, high-throughput sequencing technology. This collaboration aims to...

Merck has abandoned its major £1.3 billion research center project in London and discontinued all discovery research operations in the UK due to dissatisfaction with the local pharmaceutical...

Capsida Biotherapeutics has paused its phase I/II trial of a gene therapy for STXBP1 encephalopathy following the death of the first treated pediatric patient. The experimental viral vector...

LB Pharmaceuticals completed a $285 million Nasdaq debut, the largest biotech IPO so far in 2025, ending a seven-month dry spell for sizable listings. The company aims to finance late-stage trials...